MEBIAS holds a game-changing platform to discover next generation, pathway-selective GPCR drugs devoid of on-target side effects once thought to be unavoidable. G-protein Coupled Receptor (GPCR) therapeutics comprise ~30% of current prescribed drugs. By developing pathway-selective/biased drugs within well-understood mechanisms, the significant on-target adverse effects can be alleviated. Cell-based assays alone are inadequate...
MEBIAS holds a game-changing platform to discover next generation, pathway-selective GPCR drugs devoid of on-target side effects once thought to be unavoidable. G-protein Coupled Receptor (GPCR) therapeutics comprise ~30% of current prescribed drugs. By developing pathway-selective/biased drugs within well-understood mechanisms, the significant on-target adverse effects can be alleviated. Cell-based assays alone are inadequate to identify biased drugs. Mebias’ understanding of protein dynamics of GPCRs offers a unique advantage.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.